SCHEDULE: Mizuho Financial Group Reports 8.5% Stake in DMA Acquisition Corp.

Mizuho Financial Group, Inc. has disclosed beneficial ownership of 2,058,605 common shares, representing 8.5% of the class, in Drugs Made In America Acquisition Corp.

Summary

• Mizuho Financial Group, Inc. (and its subsidiaries Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC) has filed an amended Schedule 13G.
• The filing indicates beneficial ownership of 2,058,605 shares of common stock in Drugs Made In America Acquisition Corp.
• This ownership represents 8.5% of the total class of securities.
• The filing is an amendment, with the event date requiring the filing being June 30, 2026.
• Mizuho Financial Group is classified as a Parent Holding Company for reporting purposes.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership rather than a strategic or financial update.

Positives

• Mizuho Financial Group has a significant stake (8.5%) in Drugs Made In America Acquisition Corp., potentially indicating confidence or a strategic interest.
• The filing is an amendment, suggesting ongoing monitoring and reporting of holdings.

Negatives

• The filing does not provide any financial performance data or strategic updates for Drugs Made In America Acquisition Corp.
• The nature of Mizuho's investment (e.g., passive vs. active) is not detailed beyond beneficial ownership.

Risks

• As a Schedule 13G filing, it primarily indicates passive investment, but any shift to active involvement could represent a future risk or opportunity not detailed here.
• The filing does not disclose specific risks associated with Drugs Made In America Acquisition Corp.'s business operations.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Drugs Made In America Acquisition Corp. or Mizuho Financial Group's future intentions.

Management Comments

• Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.
• Takahiro Katsura, Managing Director, Global Corporate Function Coordination Department, signed on behalf of Mizuho Financial Group, Inc.
• Shuji Matsuura, Senior Managing Corporate Executive, Head of Global Corporate & Investment Banking, signed the Power of Attorney for Mizuho Financial Group, Inc.
• Adam Hopkins, Chief Legal Officer of Mizuho Americas LLC, signed the Power of Attorney.
• Adam Hopkins, Managing Director, General Counsel of Mizuho Securities USA LLC, signed the Power of Attorney.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, often in the SPAC or acquisition space. This filing indicates Mizuho Financial Group's passive investment in Drugs Made In America Acquisition Corp.

Stakeholder Impact

• Shareholders of Drugs Made In America Acquisition Corp. are informed of a significant institutional investor's stake.
• Mizuho Financial Group's stakeholders are informed of its investment activities and regulatory compliance.

Next Steps

• Mizuho Financial Group will continue to monitor its holdings and file amendments as required by SEC regulations.
• Drugs Made In America Acquisition Corp. may continue its business operations or pursue acquisition targets.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Mizuho Financial Group, Drugs Made In America Acquisition Corp., Common Shares, Acquisition Corp.